ISO 14971:2019 - Application of Risk Management to Medical Devices Free Practice Test — 30 Questions

Question 1

Following the successful market launch of a novel diagnostic imaging system, a series of post-market surveillance reports from a specific geographic region indicate a statistically significant increase in instances where the device\'s automated calibration sequence fails, leading to inaccurate diagnostic readings. While the initial risk assessment did not identify this specific failure mode as a high-probability event, the new data suggests a potential underestimation of its occurrence or a new contributing factor not previously considered. What is the most appropriate immediate action for the manufacturer, according to the principles outlined in ISO 14971:2019, to address this emerging risk scenario?

Accepted Answer

Initiate a comprehensive review of the risk management file, focusing on the risk analysis and evaluation related to the automated calibration sequence, and update risk control measures as necessary.

Question 2

Consider a scenario where a manufacturer of an implantable cardiac rhythm management device releases a significant firmware update. This update modifies the device\'s sensing algorithms and pacing parameters, aiming to improve patient response to certain arrhythmias. Following the implementation of this update in clinical practice, post-market surveillance data indicates a slight, but statistically significant, increase in the incidence of unexpected device inhibitions in a specific patient subgroup. According to the principles outlined in ISO 14971:2019, what is the most appropriate and comprehensive action the manufacturer must undertake in response to this development?

Accepted Answer

Conduct a thorough re-evaluation of the entire risk management file, including hazard identification, risk analysis, and risk evaluation for the updated device, to assess the impact of the firmware change on all identified risks and to identify any new risks.

Question 3

A manufacturer of an advanced diagnostic imaging system decides to implement a novel AI-driven software algorithm to enhance image reconstruction and reduce scan times. While the intention is to improve patient throughput and image quality, this modification significantly alters the internal processing of raw data and the generation of the final diagnostic output. Considering the principles outlined in ISO 14971:2019, what is the most appropriate risk management action to undertake following the successful development and initial validation of this new algorithm, prior to its integration into the production system?

Accepted Answer

Conduct a complete re-evaluation of the entire risk management file, including hazard identification, risk analysis, risk evaluation, and risk control measures for all identified hazards, to account for the impact of the new algorithm.

Question 4

A manufacturer of a novel implantable cardiac defibrillator (ICD) has successfully completed its pre-market risk assessment and received regulatory approval. Six months post-launch, a series of user reports indicate a subtle but recurring issue where the device\'s charging mechanism occasionally fails to initiate a full charge cycle, leading to a delayed response in critical situations. This phenomenon was not explicitly identified as a failure mode during the initial design and risk analysis phases. Considering the principles outlined in ISO 14971:2019, what is the most appropriate immediate action for the manufacturer to take upon receiving this aggregated user feedback?

Accepted Answer

Initiate a comprehensive review and update of the risk management file to incorporate the newly identified failure mode and its potential impact on device safety.

Question 5

A manufacturer of an implantable cardiac rhythm management device decides to update the device\'s firmware to incorporate a novel predictive algorithm designed to anticipate potential arrhythmias. This algorithm significantly alters how the device analyzes patient electrograms and adjusts pacing parameters. Following the successful integration and initial bench testing of the new firmware, what is the most critical risk management activity that must be undertaken before the device can be released with this updated functionality?

Accepted Answer

Conduct a thorough re-evaluation of the entire risk management process, including hazard identification, risk analysis, and risk evaluation for the modified device, and update the risk management file accordingly.

Question 6

Consider a scenario where a complex diagnostic imaging device, initially designed for trained radiologists in a clinical setting, is being increasingly adopted for home monitoring by patients with chronic conditions. Post-market surveillance data reveals a significant number of user-reported incidents where individuals, lacking formal medical training, misinterpret the device\'s diagnostic output indicators, leading to delayed or inappropriate self-treatment. According to ISO 14971:2019, what is the most appropriate initial step the manufacturer should take to address this emergent risk?

Accepted Answer

Initiate a comprehensive review of the existing risk management file, update the risk analysis to incorporate the home-use scenario with untrained users, and subsequently implement revised risk control measures based on the updated analysis.

Question 7

Following the successful market introduction of a novel implantable cardiac monitor, the manufacturer identifies an opportunity to enhance its data transmission protocol to improve patient data retrieval efficiency. This enhancement involves a significant software modification. According to the principles outlined in ISO 14971:2019, what is the mandatory action required of the manufacturer concerning the device\'s risk management process after implementing this software change?

Accepted Answer

Conduct a complete re-evaluation of the device's risk management file, including a thorough review of the risk analysis and risk evaluation, to identify any new or modified risks arising from the software enhancement.

Question 8

Consider a scenario where a manufacturer of an implantable cardiac defibrillator (ICD) has identified a potential risk of lead dislodgement during implantation surgery. A risk control measure involving a novel anchoring mechanism has been implemented. Following the implementation, clinical data from early post-market surveillance indicates that while the anchoring mechanism has reduced the incidence of dislodgement compared to the previous design, it has also introduced a new, albeit low-probability, risk of mechanical failure of the anchor itself, leading to potential tissue damage. According to the principles of ISO 14971:2019, what is the most appropriate subsequent action for the manufacturer to take regarding the risk management file for this ICD?

Accepted Answer

Re-evaluate the risk associated with the anchoring mechanism failure, update the risk analysis to reflect the new information, and determine the acceptability of the residual risk based on the revised assessment.

Question 9

A manufacturer of an implantable cardiac defibrillator (ICD) has identified a potential hazard where a software anomaly could lead to an unintended pacing inhibition. During the risk analysis phase, the team assigns a probability of occurrence for this specific anomaly to be \"rare\" and the severity of the resulting harm to the patient as \"critical.\" According to the principles outlined in ISO 14971:2019, what is the fundamental step required to determine the acceptability of this estimated risk?

Accepted Answer

Compare the estimated risk level against predefined risk acceptability criteria.

Question 10

A manufacturer of a pre-sterilized implantable cardiovascular stent decides to switch from gamma irradiation to ethylene oxide (EtO) sterilization to reduce costs. This change affects the manufacturing process and potentially the material properties of the stent. According to ISO 14971:2019, what is the most appropriate action regarding the existing risk management file for this device?

Accepted Answer

Conduct a comprehensive review and update of the entire risk management file, including hazard identification, risk estimation, and risk evaluation, to account for the new sterilization method and its potential effects.

Question 11

A manufacturer of a sterile implantable device decides to transition from gamma irradiation to ethylene oxide (EtO) sterilization to enhance material compatibility and reduce degradation. This change affects the device\'s manufacturing process significantly. According to the principles outlined in ISO 14971:2019, what is the most appropriate action the manufacturer must undertake regarding the device\'s risk management file following this sterilization method modification?

Accepted Answer

Conduct a comprehensive re-evaluation of the risk analysis and risk assessment to account for any new hazards or changes in risk levels introduced by the EtO sterilization process.

Question 12

A manufacturer of an implantable neurostimulator is implementing a design change to the device\'s power supply circuitry to improve battery longevity. This modification involves altering the voltage regulation components and the charging interface. Following the implementation of this design change, what is the most critical step in the risk management process according to ISO 14971:2019?

Accepted Answer

Conduct a comprehensive review and update of the entire risk management file, including re-evaluation of the risk analysis, risk evaluation, and risk control measures.

Question 13

A manufacturer is developing a next-generation, AI-driven diagnostic imaging system designed for early detection of rare pediatric cancers. The system utilizes advanced machine learning algorithms to analyze complex imaging data, aiming to improve diagnostic accuracy and reduce invasiveness compared to existing methods. When establishing the risk acceptability criteria for this device, which of the following provides the most comprehensive and appropriate foundation, considering the device\'s intended use, target population, and the broader regulatory landscape?

Accepted Answer

A synthesis of relevant national and international regulatory requirements for medical devices, coupled with an assessment of societal expectations regarding acceptable risk in pediatric healthcare.

Question 14

A manufacturer of a diagnostic imaging system has released a significant software update intended to improve image processing algorithms and expand the device\'s diagnostic capabilities. This update modifies how the system interprets certain tissue densities, potentially affecting the accuracy of diagnoses. According to the principles outlined in ISO 14971:2019, what is the most critical step the manufacturer must undertake following the implementation of this software revision?

Accepted Answer

Conduct a comprehensive risk analysis for the modified device, re-evaluating all identified hazards and risks in light of the new software.

Question 15

A medical device manufacturer is developing a novel portable ultrasound system intended for point-of-care diagnostics. During the design and development phase, the risk management team meticulously identifies potential hazards such as unintended probe overheating, electrical shock due to faulty insulation, and software malfunctions leading to incorrect diagnostic readings. For each identified hazard, they systematically estimate the probability of occurrence of the hazardous situation and the severity of the potential harm to the patient and the operator. For instance, they quantify the likelihood of probe overheating to be \"unlikely\" and the severity of associated tissue damage as \"moderate.\" This structured process of hazard identification and estimation of probability and severity is a critical step in ensuring the safety of the device. Which phase of the risk management process, as defined by ISO 14971:2019, does this detailed activity primarily represent?

Accepted Answer

Risk analysis

Question 16

Following the identification of a potential hazard associated with a novel diagnostic imaging system, a medical device manufacturer has meticulously documented the potential failure modes, estimated the probability of a specific software anomaly occurring during a critical diagnostic procedure to be $1 \times 10^{-4}$ per use, and assessed the severity of the resulting diagnostic error as "serious injury." The manufacturer has also outlined potential mitigation strategies to reduce the likelihood of the anomaly. However, before implementing these mitigations, what is the indispensable next step in the risk management process according to ISO 14971:2019 to determine if the current risk level is tolerable?

Accepted Answer

Evaluate the estimated risk against the established risk acceptability criteria.

Question 17

A medical device manufacturer is developing a new implantable cardiac rhythm management system. During the risk management process, they have meticulously identified potential hazards, such as lead fracture or device malfunction, and have estimated the probability of occurrence for each hazard, alongside the potential severity of the resulting harm to the patient. Following these estimations, the team convenes to compare the calculated risk levels against the company\'s predefined risk acceptability criteria, which are informed by relevant medical literature, clinical expert opinion, and applicable regulatory guidance from bodies like the European Medicines Agency (EMA). What specific phase of the risk management process is primarily being undertaken when this comparison against acceptability criteria is performed?

Accepted Answer

Risk evaluation

Question 18

A manufacturer of an implantable cardiac rhythm management device is preparing to release a significant firmware update. This update includes a redesigned user interface for the associated programming system and a novel algorithm for detecting and responding to specific arrhythmias. Considering the principles outlined in ISO 14971:2019, what is the most appropriate action regarding the device\'s risk management file following the implementation of this firmware update?

Accepted Answer

Conduct a comprehensive review and update of the entire risk management file, re-evaluating all identified hazards and risks in light of the new user interface and diagnostic algorithm.

Question 19

A manufacturer of an implantable cardiac defibrillator (ICD) decides to update the device\'s firmware to enhance battery life. This update involves a modification to the algorithm responsible for detecting and responding to life-threatening arrhythmias. Following the firmware deployment, a post-market surveillance report indicates a slight, but statistically significant, increase in instances where the device failed to deliver therapy during a critical event, although no patient harm has been reported yet. According to the principles outlined in ISO 14971:2019, what is the most appropriate immediate action for the manufacturer to take regarding their risk management process?

Accepted Answer

Conduct a thorough re-evaluation of the risk management file, specifically focusing on the identified failure mode, its potential causes, and the effectiveness of existing risk control measures, and consider implementing additional controls if necessary.

Question 20

Consider a scenario involving a novel diagnostic imaging device. Following the identification of a potential hazard related to software malfunction leading to incorrect diagnostic output, a risk control measure involving enhanced software validation protocols and redundant error-checking algorithms was implemented. After the implementation of these measures, what is the next critical step in the risk management process as mandated by ISO 14971:2019 to ensure the continued safety of the device?

Accepted Answer

Re-evaluate the acceptability of the residual risk based on the effectiveness of the implemented risk control measures.

Question 21

Consider a scenario where a novel, implantable biosensor, designed for continuous glucose monitoring, has been in clinical use for two years. During post-market surveillance, a trend emerges indicating a statistically significant, albeit low-frequency, occurrence of erroneous high glucose readings that could lead to inappropriate insulin dosing. This anomaly was not identified during the initial risk analysis and hazard identification phases. What is the most appropriate immediate action according to the principles of ISO 14971:2019?

Accepted Answer

Initiate a comprehensive review and update of the entire risk management file, focusing on the newly identified failure mode and its potential impact on residual risk.

Question 22

A manufacturer of a diagnostic imaging system releases a significant software update that alters the image processing algorithms and introduces new diagnostic parameter adjustments accessible to the clinician. According to the principles outlined in ISO 14971:2019, what is the mandatory action the manufacturer must undertake concerning their risk management file following this update?

Accepted Answer

Conduct a comprehensive review and, if necessary, revise the entire risk management file to account for the software modifications.

Question 23

Following the identification of a potential failure mode in a novel diagnostic imaging system that could lead to misdiagnosis, the engineering team has meticulously estimated the probability of occurrence and the severity of the potential harm. They have documented these findings in a risk analysis report. What is the immediate subsequent step mandated by ISO 14971:2019 for this specific risk before considering any mitigation strategies?

Accepted Answer

Determining the acceptability of the identified risk based on established criteria.

Question 24

A manufacturer of a diagnostic imaging system, initially intended for use in a controlled hospital laboratory environment, decides to adapt it for point-of-care testing in a less controlled clinical setting. This adaptation involves minor software modifications to streamline the user interface for non-specialist personnel and a change in the power supply to accommodate standard wall outlets. Considering the principles of ISO 14971:2019, what is the most critical action the manufacturer must undertake regarding the existing risk management file for this modified device?

Accepted Answer

Conduct a comprehensive review and revision of the entire risk management file to account for the altered intended use and its potential impact on identified hazards and risks.

Question 25

Consider a scenario where a manufacturer of an implantable cardiac pacemaker has received post-market surveillance data indicating a higher-than-anticipated rate of lead dislodgement in a specific patient demographic. This data emerged six months after the device received regulatory approval. According to the principles outlined in ISO 14971:2019, what is the most appropriate action regarding the risk management process for this medical device?

Accepted Answer

Initiate a comprehensive review of the risk management file, focusing on the identified hazard of lead dislodgement, to assess the adequacy of existing risk control measures and potentially implement additional ones.

Question 26

A medical device manufacturer has completed the risk analysis for a novel implantable cardiac monitor, identifying a potential hazard related to premature battery depletion leading to loss of monitoring function. The analysis has estimated the probability of this event occurring within the device\'s intended lifespan and the severity of the potential harm to the patient if monitoring is lost. What subsequent step is essential to determine if the identified risk is acceptable according to the medical device\'s risk management plan and relevant regulatory guidance?

Accepted Answer

Comparing the estimated risk against the organization's established risk acceptability criteria.

Question 27

A manufacturer of an implantable cardiac rhythm management device has meticulously documented a potential hazard related to unintended electrical stimulation during a specific diagnostic procedure. For this hazard, they have estimated the probability of occurrence as "rare" (occurring between $10^{-5}$ and $10^{-4}$ per year of use) and the severity of the resulting harm as "serious injury" (requiring medical intervention to prevent permanent impairment). The company has established internal risk acceptability criteria that define "serious injury" with a "rare" probability of occurrence as "acceptable without further risk control measures." Which phase of the risk management process is the manufacturer currently undertaking by comparing this estimated risk against their established acceptability criteria?

Accepted Answer

Risk evaluation

Question 28

Consider a scenario where a novel diagnostic imaging device, following its initial risk assessment and market release, experiences an unexpected failure mode identified during post-market surveillance. This newly identified failure mode, which was not anticipated during the initial design and risk analysis, has the potential to lead to a misdiagnosis if not addressed. According to the principles outlined in ISO 14971:2019, what action is most critical to ensure ongoing safety and compliance?

Accepted Answer

Initiate a comprehensive review and update of the entire risk management file, including hazard identification, risk estimation, risk evaluation, and implementation of necessary risk control measures for the newly identified failure mode.

Question 29

A medical device manufacturer is developing a novel infusion pump. During the design and development phase, the team identifies a potential hazard where a software glitch could cause the pump to deliver an incorrect dosage of medication. They then proceed to estimate the likelihood of this glitch occurring and the potential severity of the harm to the patient if it does. What specific phase of the risk management process, as defined by ISO 14971:2019, does this activity primarily represent?

Accepted Answer

Risk analysis

Question 30

A manufacturer of an implantable cardiac defibrillator (ICD) receives post-market surveillance reports indicating a novel, intermittent failure mode where the device unexpectedly ceases pacing for brief periods, leading to potential patient syncope. This failure mode was not identified during the initial design and risk analysis. What is the most appropriate immediate action according to ISO 14971:2019 principles?

Accepted Answer

Initiate a comprehensive review of the risk management process, incorporating the newly identified failure mode, assessing its impact on risk acceptability, and implementing further risk control measures if necessary.

ISO 14971:2019 - Application of Risk Management to Medical Devices Free Practice Test — 30 Questions

A lot more is already mapped out

About the ISO 14971:2019 - Application of Risk Management to Medical Devices Certification